Evidence map›Paper›PMID 39506820›Full record

ArticlePilot and feasibility studies2024

Magnetic resonance imaging-guided single-fraction preoperative radiotherapy for early-stage breast cancer (the RICE trial): feasibility study.

Ayyaz Qadir, Nabita Singh, Jenna Dean, Kerryn Brown, Mark Tacey, Bruce Mann, Tomas Kron, Glenn Cahoon, Eddie Lau, Andrew M Scott and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pilot and feasibility studies, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ayyaz QadirDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Nabita SinghDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Jenna DeanDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Kerryn BrownDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Mark TaceyDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Bruce MannRoyal Women's Hospital, Parkville, VIC, Australia.
Tomas KronMelbourne University, Parkville, VIC, Australia.
Glenn CahoonDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Eddie LauMelbourne University, Parkville, VIC, Australia.
Andrew M ScottSchool of Cancer Medicine, Olivia Newton John Cancer Research Instituteand, Latrobe University , Melbourne, VIC, Australia.
Belinda YeoSchool of Cancer Medicine, Olivia Newton John Cancer Research Instituteand, Latrobe University , Melbourne, VIC, Australia.
Su-Wen LohBreast Surgery, Austin Health, Heidelberg, VIC, Australia.
Sergio UribeDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Aung Aung Kywe MoeDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Kerryn Ireland-JenkinsMelbourne University, Parkville, VIC, Australia.
Rosly McAuleyDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Leah McDermontDepartment of Radiation Oncology, Newton-John Cancer Wellness and Research Centre, 145 Studley Road, PO Box 5555, Heidelberg , Austin HealthVictoria, Olivia, 3084, Australia.
Wei Ming OoiBreast Surgery, Austin Health, Heidelberg, VIC, Australia.
Suat NgBreast Surgery, Austin Health, Heidelberg, VIC, Australia.
Michael ChaoDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Farshad ForoudiDepartment of Medical Imaging and Radiation Sciences, School of Primary and Allied Health Care, Monash University, Melbourne, Australia. farshad.foroudi@austin.org.au.ORCID http://orcid.org/0000-0001-8387-0965

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the past decade, the adoption of screening programs, digital mammography, and magnetic resonance imaging (MRI) has increased early-stage breast cancer diagnosis rates. Mortality rates have decreased due to early detection and improved treatments, including personalized therapies. Accelerated partial-breast irradiation (APBI) is emerging as a convenient and effective treatment for some patients, with studies exploring its preoperative use. Preoperative APBI, especially with MRI guidance, offers improved tumor targeting and potentially reduced side effects. Magnetic Resonance Imaging-Guided Single-Fraction Pre-Operative Radiotherapy for Early-Stage Breast Cancer (RICE trial) aims to assess the feasibility and efficacy of MRI-guided single-dose radiotherapy (RT) for early-stage breast cancer.

methodsThe RICE study is a prospective, single-arm study evaluating single-fraction preoperative, APBI treatment for patients with early-stage breast cancer using a magnetic resonance imaging linear accelerator (MRI linac). Eligible patients enrolled in this study will have a core biopsy to confirm estrogen receptor-positive and HER2-negative sub-type. RT planning will use a planning computed tomography (CT) co-registered with a MRI with the patient in either the supine or prone position. For the diagnostic workup, [18F] fluorodeoxyglucose positron emission tomography/CT ([18F] FDG PET/CT) and [18F] fluoroestradiol positron emission tomography/CT ([18F] FES PET/CT) will be performed prior to treatment. Thirty patients will receive a single ablative RT dose of 21 Gray to the tumor. Pre-treatment and post-treatment MRI scans will be acquired at baseline and 5 weeks post-RT respectively. Breast-conserving surgery will be scheduled for 6 weeks after APBI treatment using the MRI linac. The primary study endpoint is the successful administration of a single fraction of preoperative breast RT under the guidance of an MRI linac. Secondary endpoints include evaluating the utility of MRI, [18F] FDG PET/CT, and [18F] FES PET/CT as a non-invasive method for assessing treatment response in patients undergoing single-fraction preoperative APBI.

conclusionThe RICE trial represents a significant step in breast cancer treatment, offering insights that could lead to treatment protocols with minimized RT appointments and enhanced patient outcomes.

trial registrationThis trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR). Registered 31st of May 2021. REGISTRATION NUMBER: ACTRN12621000659808 .

Indexed as

Breast cancerMagnetic resonance imagingNeoadjuvant therapyRadiation therapyResponseStudy protocol

Identifiers

PMID39506820
PMCPMC11542258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.